{{get_dataset_fail}}




{{section.text}} {{section.text}} {{section.text}} {{section.text}} {{dataset.name}}


OBJECTIVE: Sorafenib is effective in hepatocellular carcinoma (HCC), but patients ultimately present disease progression. Molecular mechanisms underlying acquired resistance are still unknown. Herein, we characterize the role of tumor-initiating cells (T-ICs) and signaling pathways involved in sorafenib resistance. DESIGN: HCC xenograft mice treated with sorafenib (n=22) were explored for responsiveness (n=5) and acquired resistance (n=17). Mechanism of acquired resistance were assessed by: 1) Role of T-ICs by in vitro sphere formation and in vivo tumorigenesis assays using NOD/SCID mice, 2) Activation of alternative signaling pathways and 3) Efficacy of anti-FGF and anti-IGF drugs in experimental models. Gene expression (microarray, qRT-PCR) and protein analyses (immunohistochemistry, western blot) were conducted. A novel gene signature of sorafenib resistance was generated and tested in 2 independent cohorts. RESULTS: Sorafenib-acquired resistance tumors showed significant enrichment of T-ICs (164 cells needed to create a tumor) vs. sorafenib-sensitive tumors (13400 cells) and non-treated tumors (1292 cells), p<0.001. Tumors with sorafenib-acquired resistance were enriched with IGF and FGF signaling cascades (FDR<0.05). In vitro, cells derived from sorafenib-acquired resistant tumors and two sorafenib-resistant HCC cell lines were responsive to IGF or FGF inhibition. In vivo, FGF blockade delayed tumor growth and improved survival in sorafenib-resistant tumors. A sorafenib-resistance 175-gene signature was characterized by enrichment of progenitor-cell features, aggressive tumoral traits and predicted poor survival in 2 cohorts (n=442 HCC patients). CONCLUSION: Acquired resistance to sorafenib is driven by tumor initiating cells with enrichment of progenitor markers and activation of IGF and FGF signaling. Inhibition of these pathways would benefit a subset of patients after sorafenib progression. Transcriptomic profile of subcutaneous Huh7 cells-derived tumors treated with sorafenib that developed acquired resistance to the drug (n=4), remain responsive to sorafenib (n=3) or were treated with brivanib after development of resistance (n=3). Gene profiling of hepatospheres generated from tumors with acquired resistance to sorafenib (n=3) and non-treated tumors (n=3) was also analyzed.

ABSTRACT: {{section.text}} {{section.text}} {{section.text}} {{section.text}} {{abstract_sections[abstract_sections.length-1].tobeReduced=='true'?"... [more]":""}} [less]

SAMPLE PROTOCOL: {{section.text}} {{section.text}} {{section.text}} {{section.text}} {{sample_protocol_sections[sample_protocol_sections.length-1].tobeReduced=='true'?"... [more]":""}} [less]

DATA PROTOCOL: {{section.text}} {{section.text}} {{section.text}} {{section.text}} {{data_protocol_sections[data_protocol_sections.length-1].tobeReduced=='true'?"... [more]":""}} [less]

REANALYSIS of: {{reanalysis_item.accession}}

REANALYZED by: {{reanalyzed_item.accession}}

OTHER RELATED OMICS DATASETS IN: {{reanalysis_item.accession}}

INSTRUMENT(S): {{instrument+';'}}

ORGANISM(S): {{organism.name + ';'}}

TISSUE(S): {{tissue+';'}}

DISEASE(S): {{disease+';'}}

SUBMITTER: {{dataset['submitter'] + ' <' + dataset['submitterMail'] + '>'}}

PROVIDER: {{acc}} | {{repositories[domain]}} | {{dataset['publicationDate'].substr(5,2)+"-"+dataset['publicationDate'].substr(8,2)+"-"+dataset['publicationDate'].substr(0,4)}}

{{publication_info[publication_index_info[dataset.publicationIds[current_publication]]].title}}

{{author.fullname.substr(0,author.fullname.length-2)}} ,

{{publication_info[publication_index_info[dataset.publicationIds[current_publication]]].citation}}


Sorry, this publication's infomation has not been loaded in the Indexer, please go directly to PUBMED or Altmetric.

ABSTRACT: {{publication_info[publication_index_info[dataset.publicationIds[current_publication]]].pub_abstract[0]}}
{{publication_info[publication_index_info[dataset.publicationIds[current_publication]]].pub_abstract[1]}} [less]

ABSTRACT: {{publication_info[publication_index_info[dataset.publicationIds[current_publication]]].pub_abstract[0]|limitTo:500}} {{publication_info[publication_index_info[dataset.publicationIds[current_publication]]].pub_abstract[0].length>500?"... [more]":""}}

Publication: {{current_publication +1}}/{{dataset.publicationIds.length}}

{{dataset.publicationIds[current_publication].publicationDate}}


Only show the datasets with similarity scores above:{{threshold}}

Threshold:
    {{threshold}}
     

The biological similarity score is calculated based on the number of molecules (Proteins, Metabolites, Genes) common between two different projects.

Similar Datasets

  • Organism: {{organism["name"]}} Not available
    {{relatedDataset['publicationDate'].substr(0,4)+"-"+relatedDataset['publicationDate'].substr(4,2)+"-"+relatedDataset['publicationDate'].substr(6,2)}}| {{relatedDataset.id}} | {{repositories[relatedDataset.source]}}